Journal article

Human papillomavirus prevalence to age 60 years among Australian women prevaccination

Julia ML Brotherton, John R Condon, Peter B McIntyre, Sepehr N Tabrizi, Michael Malloy, Suzanne M Garland

Sexual Health | CSIRO PUBLISHING | Published : 2015

Abstract

UNLABELLED: Background The prevalence of human papillomavirus (HPV) at the cervix varies with age, peaking following sexual debut and declining thereafter in most populations. In some populations, a second peak is observed. Here we describe the prevalence of HPV at the cervix among Australian women before the commencement of the HPV vaccination program. METHODS: Women aged 15 to 60 years attending health services for cervical screening between 2005 and 2008 were invited to participate. Liquid based cervical specimens were tested for 37 types of HPV using linear array. The percentage and 95% confidence interval of women with any type of HPV, any of 13 high risk HPV types, and with vaccine-pre..

View full abstract

Grants

Funding Acknowledgements

JMLB has been an investigator on investigator-designed, unrestricted, epidemiological research grants partially funded through bioCSL/Merck but has received no personal financial benefits. SNT is a chief investigator on a cancer typing study funded by a research grant from bioCSL. SMG has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GlaxoSmithKline and Sanofi Pasteur. In addition, she has received funding through her institution to conduct HPV vaccine studies for Merck Sharpe Dohme and GlaxoSmithKline. SMG is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. PBM and his affiliation have received in-kind support for research projects from GlaxoSmithKline, Pfizer, CSL Limited and Merck. JC and MM have no competing interests to declare.Funding was received from the Cooperative Research Centre for Aboriginal Health for a pilot study in Alice Springs, Northern Territory. Grants-in-aid from GlaxoSmithKline and CSL Ltd., Melbourne, Australia supported the main study. Funding organisations had no role in the design, analysis, interpretation of data or the decision to submit for publication.